Assessing red blood cell product quality with 2,3‐ DPG , ATP and p50 assays: A BEST Collaborative study
Vox Sanguinis · 2025
DOI: 10.1111/vox.70117 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Vox Sanguinis, 2025. Verfasst von Tamar P Feldman und 7 weiteren Autor:innen. Beteiligte Einrichtung: American Red Cross, Holland Lab for the Biomedical Sciences, Rockville, Maryland, USA. Hauptthemen laut MEDLINE: 2,3-Diphosphoglycerate, Adenosine Triphosphate, Erythrocytes. Die Arbeit nennt 58 Literaturangaben. Gefördert von: American Red Cross, Canadian Blood Services.
Abstract (Originalsprache)
To comply with regulatory guidelines, blood products undergo laboratory testing to assess red blood cell (RBC) quality during manufacturing, storage and delivery. Measurements of metabolites such as 2,3‐diphosphoglycerate (2,3‐DPG) have been relied upon as proxies for in vivo function, although their predictive value for clinical efficacy is not well substantiated. Following the discontinuation of the only validated commercial assay for 2,3‐DPG, we reviewed existing literature and performed a retrospective analysis of datasets from two blood centres in North America to evaluate adenosine‐5′‐triphosphate (ATP) and p50 as alternatives. The literature did not provide sufficient evidence to support adopting p50 in place of 2,3‐DPG. Although the assays are complementary, we found several exceptions in which biological and technical factors reduced the strength of correlation between 2,3‐DPG and p50. ATP, another marker of RBC quality, was not well correlated either with 2,3‐DPG or p50 in quality monitoring datasets or with in vivo circulation kinetics in healthy adults. Our assessment underscores the need for a replacement assay for 2,3‐DPG for comprehensive characterization of novel red cell products and storage conditions.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- American Red Cross, Holland Lab for the Biomedical Sciences, Rockville, Maryland, USA.
- Centre for Innovation, Canadian Blood Services, Edmonton, Alberta, Canada.
- Department of Laboratory Medicine and Pathology, University of Alberta, Edmonton, Alberta, Canada.
- American Red Cross, Norfolk Clinical Research Laboratory, Norfolk, Virginia, USA.
ORCID-Profile: Tamar P Feldman, Jason Acker, Bethany L Brown
Förderung
- American Red Cross
- Canadian Blood Services
Zitieren
APA
Feldman, T. P., Brandon-Coatham, M., Kurach, J., Olafson, C., Acker, J., Wellington, M., Brown, B. L., & Biomedical Excellence for Safer Transfusion (BEST) Collaborative (2025). Assessing red blood cell product quality with 2,3‐ DPG , ATP and p50 assays: A BEST Collaborative study. Vox Sanguinis. https://doi.org/10.1111/vox.70117
Vancouver
Feldman TP, Brandon-Coatham M, Kurach J, Olafson C, Acker J, Wellington M, et al. Assessing red blood cell product quality with 2,3‐ DPG , ATP and p50 assays: A BEST Collaborative study. Vox Sanguinis. 2025. doi:10.1111/vox.70117
BibTeX
@article{Feldman2025,
author = {Feldman, Tamar P and Brandon-Coatham, Mackenzie and Kurach, Jayme and Olafson, Carly and Acker, Jason and Wellington, Michael and Brown, Bethany L and Biomedical Excellence for Safer Transfusion (BEST) Collaborative, Biomedical Excellence for Safer Transfusion (BEST) Collaborative},
title = {Assessing red blood cell product quality with 2,3‐ DPG , ATP and p50 assays: A BEST Collaborative study},
journal = {Vox Sanguinis},
year = {2025},
doi = {10.1111/vox.70117}
}
EUVIMED